Myasthenia Gravis (MG)
9
4
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis
Efficacy of IVIG Versus PLEX in Myasthenic Crisis in Syria.
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Talquetamab in Patients With Refractory Generalized Myasthenia Gravis
Long-term Efficacy of Modified Guilu Erxian Glue for Myasthenia Gravis
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
Ripertamab for the Treatment of Myasthenia Gravis
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases